Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells

BACKGROUND: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic. Everolimus/RAD001 (Afinitor®) has had limited efficacy as a solo agent but is projected to become part of combination therapy for AI-resistant breast cancer. This study was co...

Descripción completa

Detalles Bibliográficos
Autores principales: Lui, Asona, New, Jacob, Ogony, Joshua, Thomas, Sufi, Lewis-Wambi, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947349/
https://www.ncbi.nlm.nih.gov/pubmed/27421652
http://dx.doi.org/10.1186/s12885-016-2490-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947349/
https://www.ncbi.nlm.nih.gov/pubmed/27421652
http://dx.doi.org/10.1186/s12885-016-2490-z

Ejemplares similares